Abstract: Methods and compositions for controlling ocular hypertension associated with (i) primary open angle glaucoma (POAG), (ii) other forms of glaucoma, or (iii) glucocorticoid therapy are disclosed. The methods involve administration of angiostatic agents and other IOP-lowering agents via local injections in the anterior segment of the eye. The most preferred IOP-lowering agents are angiostatic steroids, particularly anecortave acetate, and the most preferred route of administration is an anterior juxtascleral injection or implant. The invention is based in part on the discovery that anterior juxtascleral injections of anecortave acetate are capable of controlling intraocular pressure for sustained periods of from one to several months or more. This result is believed to be attributable to facilitation of access of the anecortave acetate to the trabecular meshwork via the anterior juxtascleral route of administration.

Abstract: The use of HETE compounds to treat vaginal dryness is disclosed.

Abstract: A device for the delivery of unstable pharmaceutical preparations is disclosed. The device includes an upper container for receiving a first component of the preparation and a lower container for receiving a second component of the preparation. The first and second components are unstable when mixed. Advantageous preparations for use in the device are also disclosed.

Abstract: In one embodiment, a container including a bottom container closed at a bottom end and open at a top end and having a tubular neck, a top container open at a top end and closed at a bottom by a tearable seal, a flap extending radially out from an exterior of the top container so that the flap surrounds the neck of the bottom container, and a tubular sleeve having a bottom end and a top end, the bottom end defined by a beveled edge and the top end closed by a truncated cone, the bottom end of the tubular sleeve being sized and shaped to be received within the open end of the top container. The tubular neck has a peripheral edge containing a first set of stria, and an interior of the tubular neck has a plurality of sealing rings. The top container engages the sealing rings of the bottom container, and the flap surrounds the neck of the bottom container, when the top container is inserted into the interior of the tubular neck.

Abstract: It comprises: (1) preparing an aqueous phase containing surface active suspensor agents and, optionally, a chemically or biologically active chemical substance; (2) preparing an organic phase containing a biocompatible polymer or monomer and, optionally, a lipid or chemically or biologically active chemical substance; (3) mixing both phases in a continuous manner in a constant average phase-volume ratio, continuously removing a recently formed colloidal suspension; (4) continuously eliminating the solvent from the colloidal suspension; and (5) completely eliminating the organic solvent and part or all of the water in order to obtain the desired concentration of nanospheres or dry product.Application in biomedicine, pharmacy, medicine, cosmetics, chemical industry, agriculture, veterinary science, etc.

Abstract: It comprises: 0.005-1.0% of trimethoprim or a pharmaceutically acceptable salt thereof: 0.01-0.3% of polymyxin or a pharmaceutically acceptable salt thereof: 0.001-5% of a steroidal or non-steroidal anti-inflammatory drug and, optionally, one or more ingredients selected from among isotonizing agents, pH buffers, viscosity modifying agents, wetting agents, chelating agents, anti-oxidants, preservatives and vehicles. The formulation has a pH between 4 and 8.5.It is applicable in the treatment of ophthalmic and otic infections accompanied by inflammation.